Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
73
-
Total 13F shares, excl. options
-
130M
-
Shares change
-
+1.47M
-
Total reported value, excl. options
-
$1.03B
-
Value change
-
+$4.54M
-
Put/Call ratio
-
0.52
-
Number of buys
-
40
-
Number of sells
-
-37
-
Price
-
$7.98
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q3 2020
99 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q3 2020.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 73 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 130M shares
of 1.57B outstanding shares and own 8.25% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (39M shares), NEA Management Company, LLC (17.1M shares), RA CAPITAL MANAGEMENT, L.P. (11.3M shares), Avoro Capital Advisors LLC (11M shares), Capital World Investors (8M shares), BAILLIE GIFFORD & CO (7.08M shares), BAKER BROS. ADVISORS LP (6.33M shares), CITADEL ADVISORS LLC (4.89M shares), VICTORY CAPITAL MANAGEMENT INC (2.92M shares), and RTW INVESTMENTS, LP (2.62M shares).
This table shows the top 73 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.